On October 22, the federal appeals court denied Regeneron’s request for an injunction against Amgen pending appeal, which would have forestalled the biosimilar maker’s launch of Pavblu®, its biosimilar version of Eylea® (aflibercept). In late September, a judge from the District Court for the Northern Virginia District of West Virginia refused Regeneron’s original request for … Continue reading Amgen Wins Injunction Battle Against Regeneron, Paving Way for Aflibercept Launch